top of page
Search

Medical Device Cybersecurity: Why It Matters Beyond Software as a Medical Device (SaMD)

Cybersecurity Is Now a Patient Safety Issue

Medical devices are becoming increasingly connected. From diagnostic imaging systems and patient monitoring equipment to infusion pumps and wearable health technologies, modern medical devices increasingly rely on software, wireless communication, cloud platforms, and interconnected healthcare networks.

As connectivity expands, so does the potential attack surface.

Cybersecurity is no longer simply an IT issue or a concern limited to software companies. For medical device manufacturers, it has become an essential part of product safety, quality management, regulatory compliance, and long-term market readiness.

A cybersecurity incident involving a medical device can have consequences beyond the exposure of sensitive patient information. Depending on the device and the nature of the vulnerability, it may affect device functionality, interrupt healthcare services, compromise clinical data, or create risks to patient safety.

For manufacturers planning to enter the U.S. market, understanding FDA's cybersecurity expectations is increasingly important.

1. Cybersecurity Risks Extend Beyond SaMD

Software as a Medical Device (SaMD) often receives significant attention in cybersecurity discussions. However, cybersecurity considerations are not limited to standalone medical software.

Many conventional medical devices now incorporate digital and network-connected capabilities.

Examples include:

  • Patient Monitoring Systems: Devices that transmit patient vital signs and clinical information to centralized monitoring systems.

  • Medical Imaging Equipment: MRI, CT, and other imaging systems that connect to hospital networks and transfer sensitive diagnostic data.

  • Infusion Pumps: Connected devices that may communicate with hospital information systems and medication management platforms.

  • Diagnostic Equipment: Laboratory and point-of-care testing systems that rely on software, network connections, and digital data exchange.

  • Wearable Medical Devices: Connected devices that transmit patient health information to mobile applications or cloud-based platforms.

These devices may face risks such as unauthorized access, malware, data manipulation, service disruption, and exploitation of software vulnerabilities.

The important distinction is that a device does not need to be classified as SaMD to have cybersecurity risks.

2. What Does FDA Require? Understanding Section 524B

The FDA's cybersecurity framework includes Section 524B of the Federal Food, Drug, and Cosmetic (FD&C) Act, titled Ensuring Cybersecurity of Devices.

Effective March 29, 2023, this provision established specific cybersecurity requirements for medical devices that meet the statutory definition of a "cyber device."

Under Section 524B(c), a cyber device generally meets three criteria:

  1. It includes software validated, installed, or authorized by the manufacturer as a device or in a device.

  2. It has the ability to connect to the internet.

  3. It contains technological characteristics that could be vulnerable to cybersecurity threats.

For qualifying cyber devices, manufacturers submitting applicable premarket applications or submissions must address three key requirements:

A. Postmarket Cybersecurity Vulnerability Management

Manufacturers must submit a plan to monitor, identify, and address cybersecurity vulnerabilities and exploits after the device enters the market.

This includes coordinated vulnerability disclosure procedures and processes for responding to identified security issues.

B. Processes for Security Updates and Patches

Manufacturers must design, develop, and maintain processes to provide reasonable assurance that the device and related systems are cybersecure.

They must also make postmarket updates and patches available to address cybersecurity vulnerabilities.

This highlights an important principle: cybersecurity responsibilities do not end when a device receives FDA clearance or approval.

C. Software Bill of Materials (SBOM)

Manufacturers must provide a Software Bill of Materials (SBOM) identifying the software components included in the device.

This includes commercial, open-source, and off-the-shelf software components.

An SBOM helps manufacturers and other stakeholders understand the software supply chain and identify components that may be affected by known vulnerabilities.

3. FDA's February 2026 Cybersecurity Guidance: What Manufacturers Should Know

On February 3, 2026, FDA issued its updated final guidance:

Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions.

The guidance supersedes the June 27, 2025 version and incorporates updates aligned with the Quality Management System Regulation (QMSR).

It provides recommendations for medical device cybersecurity throughout product development and regulatory submission processes.

Key areas addressed include:

  • Cybersecurity Risk Management: Identifying and assessing cybersecurity risks that could affect device safety and effectiveness.

  • Threat Modeling: Evaluating potential threats, attack paths, and vulnerabilities within the device and its operating environment.

  • Security Architecture: Designing appropriate security controls and documenting how the device protects against cybersecurity threats.

  • Cybersecurity Testing: Conducting security testing, including vulnerability assessments and penetration testing, where appropriate.

  • Cybersecurity Labeling: Providing relevant information to help users understand cybersecurity considerations and maintain secure device operation.

  • Software Bill of Materials: Documenting software components and identifying potential vulnerabilities within the software supply chain.

One important point: FDA's premarket cybersecurity guidance recommendations are applicable to medical devices that have or are software, including devices that may not meet the statutory definition of a cyber device under Section 524B.

This distinction matters. The statutory requirements of Section 524B apply to qualifying cyber devices, while FDA's broader cybersecurity recommendations have a wider scope.

4. Cybersecurity Does Not End After FDA Clearance

Obtaining 510(k) clearance, De Novo authorization, or PMA approval does not eliminate cybersecurity responsibilities.

Software components may develop new vulnerabilities over time. Third-party software providers may discontinue support, security threats may evolve, and previously unknown vulnerabilities may become exploitable.

For this reason, FDA emphasizes ongoing cybersecurity risk management throughout a medical device's lifecycle.

Manufacturers should establish processes to:

  • Monitor newly identified software vulnerabilities.

  • Evaluate the potential impact of vulnerabilities on device safety and performance.

  • Establish procedures for security updates and patches.

  • Coordinate vulnerability disclosures when appropriate.

  • Maintain communication with healthcare providers and relevant stakeholders.

  • Document cybersecurity risk assessments and corrective actions.

For manufacturers, this means cybersecurity needs to be integrated into postmarket surveillance and quality management processes rather than handled as an isolated technical function.

5. What Should Medical Device Manufacturers Do Now?

Companies preparing for U.S. market entry should consider cybersecurity early in product development.

A practical starting point includes:

1. Evaluate Device Connectivity

Identify whether the device includes software, wireless communication, network connectivity, cloud integration, or other technologies that may introduce cybersecurity risks.

2. Establish a Cybersecurity Risk Management Process

Identify potential threats and assess how cybersecurity vulnerabilities could affect device safety, effectiveness, and intended use.

3. Review Software Components

Maintain visibility into third-party and open-source software components. Develop and maintain an appropriate SBOM.

4. Prepare for FDA Premarket Submissions

Evaluate applicable FDA cybersecurity documentation recommendations and determine whether Section 524B requirements apply to the device.

5. Establish Postmarket Security Procedures

Develop a structured approach for vulnerability monitoring, incident response, software updates, and security patches.

6. Integrate Cybersecurity into the Quality Management System

Ensure cybersecurity processes are appropriately incorporated into design and development, risk management, supplier controls, and postmarket activities.

Conclusion: Cybersecurity Is Part of Medical Device Safety

The medical device industry is moving toward an increasingly connected healthcare environment. While digital technologies create opportunities for innovation and improved patient care, they also introduce new cybersecurity risks that manufacturers must be prepared to manage.

For companies entering the U.S. market, FDA cybersecurity expectations should be considered alongside other regulatory requirements—not as an afterthought, but as part of the overall product development and compliance strategy.

Ultimately, a medical device must do more than function as intended. It must also be designed, maintained, and supported with appropriate safeguards against evolving cybersecurity threats.

Cybersecurity is not just about protecting systems. It is about protecting patients.

References:

  • FDA, Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions (February 3, 2026).

  • FDA, Cybersecurity Resources for Medical Device Manufacturers: Guidance, Resources, and FAQs.

  • FD&C Act, Section 524B – Ensuring Cybersecurity of Devices.

 
 

© 2022-2026 Nexgen Health Group, Inc. All Rights Reserved.

bottom of page